You have accessJournal of UrologyCME1 Apr 2023MP33-01 RISK OF RESIDUAL TERATOMA AFTER COMPLETE RESPONSE FOLLOWING FIRST-LINE CHEMOTHERAPY IN MEN WITH METASTATIC NON-SEMINOMATOUS GERM CELL TUMOR AND IGCCCG INTERMEDIATE/POOR PROGNOSIS: A MULTI-INSTITUTIONAL RETROSPECTIVE COHORT STUDY Luca Antonelli, Davide Ardizzone, Praful Ravi, Christopher Sweeney, Aditya Bagrodia, Michal Mego, Sia Daneshmand, Patrizia Giannatempo, Sebastiano Nazzani, Andrea Franza, Axel Heidenreich, Pia Paffenholz, Ragheed Saoud, Scott Eggener, Matthew Ho, Nathaniel Oswald, Alexey Tryakin, Natacha Naoun, Christophe Javaud, Villejuif Cedex, Antoin Douglawi, Clint Cary, Jennifer M. King, Nabil Adra, and Christian D. Fankhauser Luca AntonelliLuca Antonelli More articles by this author , Davide ArdizzoneDavide Ardizzone More articles by this author , Praful RaviPraful Ravi More articles by this author , Christopher SweeneyChristopher Sweeney More articles by this author , Aditya BagrodiaAditya Bagrodia More articles by this author , Michal MegoMichal Mego More articles by this author , Sia DaneshmandSia Daneshmand More articles by this author , Patrizia GiannatempoPatrizia Giannatempo More articles by this author , Sebastiano NazzaniSebastiano Nazzani More articles by this author , Andrea FranzaAndrea Franza More articles by this author , Axel HeidenreichAxel Heidenreich More articles by this author , Pia PaffenholzPia Paffenholz More articles by this author , Ragheed SaoudRagheed Saoud More articles by this author , Scott EggenerScott Eggener More articles by this author , Matthew HoMatthew Ho More articles by this author , Nathaniel OswaldNathaniel Oswald More articles by this author , Alexey TryakinAlexey Tryakin More articles by this author , Natacha NaounNatacha Naoun More articles by this author , Christophe JavaudChristophe Javaud More articles by this author , Villejuif CedexVillejuif Cedex More articles by this author , Antoin DouglawiAntoin Douglawi More articles by this author , Clint CaryClint Cary More articles by this author , Jennifer M. KingJennifer M. King More articles by this author , Nabil AdraNabil Adra More articles by this author , and Christian D. FankhauserChristian D. Fankhauser More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000003266.01AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Current guidelines recommend surveillance for men with metastatic non-seminomatous germ cell tumours (NSGCT) treated with first-line chemotherapy who had a complete clinical response to treatment (i.e., normalization of serum tumour markers and residual masses <1 cm). However, this recommendation is based on case series with classification by the International Germ Cell Cancer Cooperative Group prognostic group (IGCCCG-PG). The aim of this study was to analyse the proportion of residual teratoma and survival among male patients with intermediate or poor IGCCCG-PG and complete clinical response after first-line chemotherapy. METHODS: Retrospective study of men with intermediate or poor IGCCCGP-PG who had a complete clinical response after first-line chemotherapy. Men were followed or treated with post-chemotherapy retroperitoneal lymph node dissection (pcRPLND). Descriptive analyses and Cox regression were used to assess whether pcRPLND or surveillance leads to a longer overall survival (OS) for patients. RESULTS: Between 2009–2018, 143 men with intermediate (n = 83) or poor (n = 60) IGCCCG-PG were treated at 11 international centres. Among 33 patients treated with pcRPLND, the specimen showed teratoma and vital cancer in 16 (48%) and 4 (12%). During a median 7-year follow-up, 20/110 (18%) patients managed with surveillance relapsed, of whom 7 (6%) had a retroperitoneal-only relapse, vs 2/33 patients managed with pcRPLND relapsed. No difference was observed regarding OS among men treated with pcRPLND or surveillance (5-year OS, 93% and 89%, p-value=0.35). The median time-to-recurrence among men on surveillance was 1.3 years (range: 0.3–9.1), and the most common sites of relapses included retroperitoneum (11%), chest (5%), and bones (4%). CONCLUSIONS: While most men with intermediate/poor IGCCCG-PG harbour teratoma/cancer in the retroperitoneum despite a complete response to first-line chemotherapy, only 6% managed with surveillance relapsed in the retroperitoneum. There was no significant difference in OS between the two groups. Source of Funding: None © 2023 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 209Issue Supplement 4April 2023Page: e450 Advertisement Copyright & Permissions© 2023 by American Urological Association Education and Research, Inc.MetricsAuthor Information Luca Antonelli More articles by this author Davide Ardizzone More articles by this author Praful Ravi More articles by this author Christopher Sweeney More articles by this author Aditya Bagrodia More articles by this author Michal Mego More articles by this author Sia Daneshmand More articles by this author Patrizia Giannatempo More articles by this author Sebastiano Nazzani More articles by this author Andrea Franza More articles by this author Axel Heidenreich More articles by this author Pia Paffenholz More articles by this author Ragheed Saoud More articles by this author Scott Eggener More articles by this author Matthew Ho More articles by this author Nathaniel Oswald More articles by this author Alexey Tryakin More articles by this author Natacha Naoun More articles by this author Christophe Javaud More articles by this author Villejuif Cedex More articles by this author Antoin Douglawi More articles by this author Clint Cary More articles by this author Jennifer M. King More articles by this author Nabil Adra More articles by this author Christian D. Fankhauser More articles by this author Expand All Advertisement PDF downloadLoading ...